<DOC>
	<DOCNO>NCT00765102</DOCNO>
	<brief_summary>This phase II , open-label , multicenter , dual-strata study design evaluate efficacy safety IV romidepsin give combination IV bortezomib multiple myeloma ( MM ) patient refractory relapsed disease . Patients enrol one two stratum , bortezomib-resistant bortezomib non-resistant .</brief_summary>
	<brief_title>Trial Romidepsin Bortezomib Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Inclusion Criteria Patients must fulfill follow criterion eligible study participation : Male female patient age ≥ 18 year old Has give voluntary write informed consent studyrelated procedure part normal medical care , understand consent may withdraw patient time without prejudice future medical care Previously diagnose multiple myeloma ( MM ) base standard criterion follow : Major criterion : 1 . Plasmacytomas tissue biopsy . 2 . Bone marrow plasmacytosis ( &gt; 30 % plasma cell ) . 3 . Monoclonal immunoglobulin spike serum electrophoresis IgG &gt; 3.5 g/dL IgA &gt; 2.0 g/dL ; kappa lambda light chain excretion &gt; 1 g/day 24 hour urine protein electrophoresis Minor criterion : 1 . Bone marrow plasmacytosis ( 10 30 % plasma cell ) 2 . Monoclonal immunoglobulin present less magnitude give major criterion 3 . Lytic bone lesion . 4 . Normal IgM &lt; 50 mg/dL , IgA &lt; 100 mg/dL IgG &lt; 600 mg/dL Any follow set criterion confirm diagnosis MM : Any two major criterion Major criterion 1 plus minor criterion 2 , 3 , 4 . Major criterion 3 plus minor criterion 1 3 . Minor criterion 1 , 2 , 3 1 , 2 , 4 . Currently MM : Measurable disease , define monoclonal immunoglobulin spike serum electrophoresis &gt; =1 gm/dL and/or urine monoclonal immunoglobulin spike &gt; =200 mg/24 hour , evidence lytic bone disease Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Lifeexpectancy &gt; 3 month All woman childbearing potential must use effective barrier method contraception . Male patient use barrier method contraception treatment period 3 month thereafter Patients must meet follow laboratory criterion Baseline ( Day 1 Cycle 1 , study drug administration ) : Platelet count ≥ 100*10^9/L Absolute neutrophil count ≥ 1.5*10^9/L OR bone marrow extensively infiltrated Platelet count ≥ 75*10^9/L Absolute neutrophil count ≥ 1.0*10^9/L Patients must meet follow laboratory criterion Screening visit conduct within 14 day enrollment ( Day 1 , Cycle 1 ) : Aspartate transaminase/serum glutamic oxaloacetic transaminase ( AST/SGOT ) alanine transaminase/serum glutamic pyruvic transaminase ( ALT/SGPT ) ≤ 3.0*upper limit normal ( ULN ) Serum bilirubin ≤ 2.0*ULN Calculated measure creatinine clearance : ≥30 mL/minute . Patient creatinine &gt; 10mL/min &lt; 30 mL/min due significant myelomatous involvement kidney may enrol study receipt approval lead investigator sponsor Serum potassium ≥ 3.8 mmol/L Serum magnesium &gt; 1.8 mg/dL Serum phosphorus ≥ low limit normal ( LLN ) Exclusion Criteria Patients ineligible entry follow criterion meet : Chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) thalidomide , lenalidomide , arsenic trioxide , bortezomib , glucocorticosteroids within 3 week prior first dose romidepsin Prior major surgery within 3 week prior first day treatment Use investigational agent within 4 week study entry Prior therapy romidepsin Any known cardiac abnormality : Congenital long QT syndrome ; QTc interval ≥ 500 millisecond ; Myocardial infarction within 6 month Day 1 . Subjects history myocardial infarction 6 12 month prior first day cycle one asymptomatic negative cardiac risk assessment ( treadmill stress test , nuclear medicine stress test , stress echocardiogram ) since event may participate ; Other significant electrocardiogram ( ECG ) abnormalities include 2nd degree atrioventricular ( AV ) block type II , 3rd degree AV block , bradycardia ( ventricular rate le 50 beats/min ) ; Symptomatic coronary artery disease ( CAD ) , e.g. , angina Canadian Class IIIV In patient doubt , patient stress image study , abnormal , angiography define whether CAD present ; An ECG record screen show evidence cardiac ischemia ( ST depression depression ≥2 mm , measure isoelectric line ST segment ) . If doubt , patient stress image study , abnormal , angiography define whether CAD present ; Congestive heart failure ( CHF ) meet New York Heart Association ( NYHA ) Class II IV definition and/or ejection fraction &lt; 40 % Multi Gated Acquisition Scan ( MUGA scan ) &lt; 50 % echocardiogram and/or MRI ; A known history sustain ventricular tachycardia ( VT ) , ventricular fibrillation ( VF ) , Torsade de Pointes , cardiac arrest unless currently address automatic implantable cardioverter defibrillator ( AICD ) ; Hypertrophic cardiomegaly restrictive cardiomyopathy prior treatment cause ; Uncontrolled hypertension , i.e. , blood pressure ( BP ) ≥160/95 ; patient history hypertension control medication must stable dose ( least one month ) meet inclusion criterion ; Any cardiac arrhythmia require antiarrhythmic medication ( exclude stable dos betablockers ) POEMS syndrome ( plasma cell dyscrasia polyneuropathy , organomegaly , endocrinopathy , monoclonal protein ( Mprotein ) skin change ) Plasma cell leukemia Primary amyloidosis Patients prior malignancy within last 5 year ( except basal squamous cell carcinoma , situ cancer cervix ) Severe hypercalcemia , i.e. , serum calcium ≥14 mg/dL ( 3.5 mmol/L ) Known infection human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C Other concurrent severe and/or uncontrolled medical psychiatric condition . Concomitant use drug may cause prolongation QTc Concomitant use CYP3A4 inhibitor Patients hypersensitivity bortezomib , boron mannitol Patients pregnant breastfeeding Patients significant history noncompliance medical regimen unwilling unable comply instruction give him/her study staff</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Multiple Myelonoma</keyword>
	<keyword>Romidepsin</keyword>
	<keyword>Bortezomib</keyword>
</DOC>